SCHEMBL4277738

SCHEMBL4277738

Cc1cc(N)c(Cl)cc1Sc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ KMT2A Q03164 3/20 0.43
▸ ALDH1A1 P00352 4/20 0.43
▸ HPGD P15428 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ PDE7A Q13946 2/20 0.41
▸ NPSR1 Q6W5P4 3/20 0.39
▸ LMNA P02545 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CD44 P16070 1/20 0.37
▸ HTR1A P08908 2/20 0.36
▸ HTR3A P46098 2/20 0.36
▸ DHFR P00374 1/20 0.35
▸ RHEB Q15382 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ L3MBTL1 Q9Y468 2/20 0.35
▸ RXFP1 Q9HBX9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4276593 0.81 MEN1 (0.40) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4284955 0.75 PDE7A (0.50) MAPTMEN1KMT2AALDH1A1PDE7A
SCHEMBL4610392 0.74 MAPT (0.53) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL810286 0.71 ALDH1A1 (0.56) MAPTALDH1A1HPGDKDM4EPDE7A
SCHEMBL4277853 0.71 PTGES (0.45) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL4277854 0.71 PTGES (0.45) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL9487284 0.69 CYP3A4 (0.56) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL6562610 0.68 MAPT (0.42) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL14364042 0.68 HTR1A (0.36) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL11224257 0.67 MEN1 (0.50) MAPTMEN1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102304075-A Inhibitors of viral replication INTERMUNE INC 2012-01-04 — — CN disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 — — US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 — — US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 — — US disclosed
CN-101304976-A Inhibitors of viral replication INTERMUNE INC (US) 2008-11-12 — — CN disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 MAPT 4203/4885MEN1 4395/4885KMT2A 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback